{"id":"flexpen-novolog","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"NovoLog (insulin aspart) is a recombinant human insulin analog with a rapid onset of action, typically beginning to work within 10-20 minutes of injection. It mimics the body's natural insulin response to meals by binding to insulin receptors on muscle and fat cells, promoting glucose uptake and storage while inhibiting hepatic glucose production. This rapid action makes it suitable for mealtime insulin therapy in diabetes management.","oneSentence":"NovoLog is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:12:49.258Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT03760068","phase":"PHASE3","title":"Mylan Insulin Aspart Study","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2018-11-07","conditions":"Diabetes Mellitus, Type 1","enrollment":478},{"nctId":"NCT04226105","phase":"PHASE3","title":"Efficacy and Safety of GP40081 Сompared to NovoMix® 30 FlexPen® in Type 2 Diabetes Mellitus Patients","status":"UNKNOWN","sponsor":"Geropharm","startDate":"2020-01-20","conditions":"Diabetes Mellitus, Type 2, Diabetes Mellitus","enrollment":264},{"nctId":"NCT03374774","phase":"","title":"A Non-interventional Study of Ability and Willingness to Pay for BIAsp 30 in a Real World Population With Type 2 Diabetes Mellitus (T2DM)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2017-11-13","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":516},{"nctId":"NCT00773279","phase":"PHASE3","title":"Efficacy, Safety and Preference Study of a Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in Diabetics","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-09","conditions":"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":242},{"nctId":"NCT01467401","phase":"PHASE4","title":"Efficacy and Safety of NovoMix® 30 in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-08-19","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":292},{"nctId":"NCT01704378","phase":"PHASE4","title":"Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen™ in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2001-04-18","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":89},{"nctId":"NCT01536626","phase":"","title":"Switch From Premixed Human Insulin to Biphasic Insulin Aspart in the Netherlands","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-06-09","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":211},{"nctId":"NCT01427920","phase":"PHASE4","title":"Comparison of Biphasic Insulin Aspart 30 Individually Adjusted by the Subject and the Trial Physician, Both Combined With Metformin in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2011-09","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":348},{"nctId":"NCT00127296","phase":"PHASE1","title":"Reliability of Dosing With NovoLog® Mix 70/30 FlexPen® Compared With Vial and Syringe","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2005-07","conditions":"Diabetes, Diabetes Mellitus, Type 2, Delivery Systems","enrollment":60},{"nctId":"NCT00600366","phase":"PHASE4","title":"Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen® in Insulin Naive Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-03","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":71},{"nctId":"NCT00715663","phase":"","title":"Observational Study to Evaluate Safety, Efficacy and Convenience of Using NovoMix® 30 FlexPen® in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-02","conditions":"Diabetes, Diabetes Mellitus, Type 2, Delivery Systems","enrollment":1584},{"nctId":"NCT01490112","phase":"","title":"Surveillance Study of NovoRapid® for New Drug Re-examination","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2005-01","conditions":"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":1239},{"nctId":"NCT01536613","phase":"","title":"Post Marketing Surveillance Study of Biphasic Insulin Aspart 30","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-09","conditions":"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":5346},{"nctId":"NCT00709683","phase":"","title":"Observational Study to Evaluate the Safety of NovoMix® 30 FlexPen®","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-05","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":216},{"nctId":"NCT01487421","phase":"","title":"An Observational Study of Insulin Aspart and, if Necessary, Insulin Levemir (FlexPen®) in the Evening or at Bedtime","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2003-07","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":2134},{"nctId":"NCT00965549","phase":"PHASE4","title":"Comparison of a Basal Plus One Insulin Regimen With a Biphasic Insulin Regimen in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-07","conditions":"Diabetes Mellitus, Type 2","enrollment":463}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"FlexPen NovoLog®","genericName":"FlexPen NovoLog®","companyName":"Mylan Inc.","companyId":"mylan-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FlexPen NovoLog is a medication used to treat diabetes, specifically Type 1 and Type 2 diabetes mellitus. It works as an insulin receptor agonist, binding to the insulin receptor to stimulate insulin activity.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}